NEW YORK (GenomeWeb News) – Cancer diagnostics services firm BioTheranostics today announced a contract with preferred provider organization Three Rivers Provider Network.

The contract covers the San Diego firm's testing services, including CancerType ID for diagnosing metastatic cancer, and Breast Cancer Index for predicting the risks of recurrence of early stage, estrogen receptor-positive breast cancer. The agreement makes BioTheranostics' tests available to an additional 15 million covered lives in the US, the firm said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: new gene linked to ocular coloboma, new statistical model for interrogating gene expression networks, and more.

With a new collection, PLOS highlights negative results it has published.

A pair of researchers examines political leanings and views on genomics, finding more of a role for optimism and pessimism in people's views.

The genome of the carnivorous bladderwort is smaller than many other plant genomes, but it still holds on to important genes.